Works in Cancer Chemotherapy & Pharmacology, 2023, Vol 91, Issue 6

Results: 8

Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 507, doi. 10.1007/s00280-023-04538-3
By:
- Korver, Samantha K.;
- Bowen, Joanne M.;
- Gibson, Rachel J.;
- Ball, Imogen A.;
- Secombe, Kate R.;
- Wain, Taylor J.;
- Logan, Richard M.;
- Tuke, Jonathan;
- Mead, Kelly R.;
- Richards, Alison M.;
- Karapetis, Christos S.;
- Keefe, Dorothy M.;
- Coller, Janet K.
Publication type:
Article
Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 481, doi. 10.1007/s00280-023-04537-4
By:
- Suzuki, Yusuke;
- Naito, Takafumi;
- Shibata, Kaito;
- Hosokawa, Seiji;
- Kawakami, Junichi
Publication type:
Article
Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 523, doi. 10.1007/s00280-023-04536-5
By:
- Hu, Chaoying;
- Zhang, Yanping;
- Pei, Tong;
- Liu, Ping;
- Zhang, Lan
Publication type:
Article
The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 501, doi. 10.1007/s00280-023-04535-6
By:
- Tsuchiya, Masami;
- Obara, Taku;
- Kikuchi, Masafumi;
- Mano, Nariyasu
Publication type:
Article
Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 491, doi. 10.1007/s00280-023-04534-7
By:
- Jang, Seong;
- Strickland, Bill;
- Finis, Lynda;
- Kooijman, Jeffrey J.;
- Melis, Janneke J. T. M.;
- Zaman, Guido J. R.;
- Van Tornout, Jan
Publication type:
Article
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 457, doi. 10.1007/s00280-023-04530-x
By:
- Patel, Ankit;
- Bhatt, Niraj;
- Prakash, S. S.;
- Biswas, Ghanashyam;
- Nagarkar, Rajnish;
- Roy, Bodhisatta;
- Samal, Priyanka;
- Agrawal, Narendra;
- Meshram, Sushil;
- Kaushal, Ashish;
- Satheesh, C. T.;
- Wategaonkar, Ravikumar;
- Thiagarajan, Kasi Viswanathan;
- Jain, Kartikeya;
- Vijayaveeran, P.;
- Mukherjee, Kalyan;
- Singh, Kishore;
- Patil, Tushar;
- Jain, Amit;
- Dolai, Tuphan Kanti
Publication type:
Article
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 469, doi. 10.1007/s00280-023-04527-6
By:
- Yamamoto, Noboru;
- Koyama, Takafumi;
- Shimizu, Toshio;
- Todaka, Akiko;
- Kawakami, Takeshi;
- Erzen, Damijan;
- Sarashina, Akiko;
- Li, Bin;
- Hou, Jianrui;
- Yamazaki, Kentaro
Publication type:
Article
Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 6, p. 447, doi. 10.1007/s00280-023-04517-8
By:
- Groenland, Stefanie L.;
- Janssen, J. M.;
- Nijenhuis, C. M.;
- de Vries, N.;
- Rosing, H.;
- Wilgenhof, S.;
- van Thienen, J. V.;
- Haanen, J. B. A. G.;
- Blank, C. U.;
- Beijnen, J. H.;
- Huitema, A. D. R.;
- Steeghs, N.
Publication type:
Article